Navigation Links
Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
Date:2/27/2009

The Company previously announced that the Phase 2 results with AT2220 will be available in the second half of 2009. The Company will provide updated guidance for reporting results in the upcoming months.

These events have no impact on Amicus' ongoing studies with its investigational drugs Amigal(TM) (migalastat hydrochloride) for Fabry disease and Plicera(TM) (afegostat tartrate) for Gaucher disease.

About the Phase 2 Trial with AT2220

Amicus initiated a multi-national, open-label Phase 2 clinical trial designed to enroll 18 adult patients diagnosed with Pompe disease. The primary objective of the study is to evaluate the safety and tolerability of different dosing regimens of AT2220 over a 12-week period. The study will also explore certain pharmacodynamic and pharmacokinetic measures including the effect of treatment with AT2220 on GAA activity and on glycogen levels in various cells and tissues. Additional objectives include preliminary assessments of pulmonary and skeletal muscle function. Participants who complete the study may be eligible to participate in a voluntary extension study that will further evaluate the effect of AT2220 on these functional parameters.

Additional information about the Phase 2 study is posted at www.clinicaltrials.gov.

The initiation of the Phase 2 study of AT2220 followed completion of multiple Phase 1 studies of AT2220 in healthy volunteers. Data from the Phase 1 studies in 72 healthy volunteers demonstrated that AT2220 was generally safe and well tolerated at all doses evaluated with no drug-related serious adverse events.

Amicus is developing AT2220 as part of a strategic collaboration with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosoma
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... BARCELONA , April 26, 2015 Cancer ... VAR ) supported project in the area of ... "big data" for the benefit of patients. Speakers at ... (European Society for Therapeutic Radiation Oncology) forum in Barcelona ... each treatment and applying that knowledge to help benefit ...
(Date:4/24/2015)... YORK , April 24, 2015   ... Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: ... statements to investors in violation of the federal ... of Aerie breached their fiduciary duties to shareholders. ... focused on the discovery, development and commercialization of ...
(Date:4/24/2015)... N.J. , April 24, 2015  IGI Laboratories, ... based specialty generic pharmaceutical company, announced the ... ET on Tuesday, April 28, 2015 to discuss the ... you to listen to the call by dialing 1-888-346-3479. ... 1-855-669-9657.  Participants should ask to be joined into the ...
Breaking Medicine Technology:Cancer Experts Detail How 'Big Data' Plays a Critical Role in Improving Clinical Decision-Making in Oncology Treatments at 3rd ESTRO Forum 2Cancer Experts Detail How 'Big Data' Plays a Critical Role in Improving Clinical Decision-Making in Oncology Treatments at 3rd ESTRO Forum 3Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc. 2
... Dec. 2, 2010 BugLab LLC, the industry leader ... – the world,s first handheld sensor for measuring optical ... device removes the need to open shake flasks to ... through the container wall, the labor, contamination risk, and ...
... 2010 SeQual Technologies, Inc., a pioneer in portable ... be acquired by Chart Industries, wholly owned subsidiary, CAIRE ... home health care market. SeQual has built a strong ... focus. As a leader in portable oxygen concentrators, SeQual ...
Cached Medicine Technology:BugLab Launches World's First Handheld Non-invasive Optical Density Sensor 2SeQual Technologies to be Acquired by Chart Industries 2
(Date:4/27/2015)... OR (PRWEB) April 27, 2015 Doping ... as Lance Armstrong and Alex Rodriguez continue to capture ... neurology present a new frontier in performance enhancement along ... SCI TV , accomplished neuroscientist Anjan Chatterjee ... talks about the ethics and dangers of these enhancements ...
(Date:4/27/2015)... Launched by a group of ... consumers a way to connect to top local ... a patent-pending Pick Your Price matching algorithm, clients ... laser hair removal and dermal fillers on days ... in their schedules. This allows clients to take ...
(Date:4/26/2015)... NC (PRWEB) April 26, 2015 Italian ... the deadly legacy of asbestos cement plants and other ... on the new research. Click here to read ... from Italy’s Department of Occupational and Environmental Medicine analyzed ... 2008 and found 32 clusters where the asbestos cancer ...
(Date:4/26/2015)... From March 18th, 2015 toward the middle of ... Trivedi, spent a month traveling in India to find ... the efforts of creating highly advanced, effective and less ... health care. , During their journey, they met ... lab facilities are approved by the U.S. Food and ...
(Date:4/26/2015)... April 26, 2015 In an article ... University evaluated the head-neck biomechanics occurring during the use of ... were able to determine that use of a tablet increases ... to 5 times - more than when the neck is ... such a study, but pointing out the potential hazards of ...
Breaking Medicine News(10 mins):Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 3Health News:ZendyBeauty Is Pleased to Announce the Expansion and Rebranding of the Company as ZendyHealth.com 2Health News:New Investigation Finds Mesothelioma “Clusters” Around Italian Cement Plants, According to Surviving Mesothelioma 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 2Health News:Trivedi Science™ Has Started Scientific Research to Create More Effective Pharmaceuticals and Nutraceuticals 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4
... study by a researcher at Karolinska Institutet in Sweden ... brain cells . ,The finding also helps ... ,Previous research had shown that exercise has similar effect ... found that this process happens as exercise stimulates the ...
... revealed that the secret of his relatively wrinkle-free visage at the ... ,The slender rock star, notorious for his wild ... applies a special cream under his eyes in order to keep ... the Daily Express quotes him as saying. ,"I ...
... (WFP) today announced plans to assist the Government of Timor-Leste ... communities affected by an ongoing drought. ,"There is ... the drought, and we will work closely with the Government ... said Tarek Elguindi, WFP Representative in Dili, Timor Leste. ...
... has announced a funding of 102 million pounds (Rs.816 ... phase of Government of India's (GOIs) National AIDS Control Programme ... comprehensive prevention, care and support programme to halt and begin ... announcement was made by Susanna Moorehead, Head of DFID India ...
... Wiliam's ex-girlfriend Kate Middleton's curvaceous figure has suddenly gone too ... style for her slender but athletic figure, is donning a ... appearances Kate appeared painfully thin, bony and almost flat chested. ... loss is due to the strain following her split with ...
... Klass has followed in the footsteps of actress Demi Moore, by ... Celebrity star, wearing only her engagement ring and a butterfly necklace, ... think, 'Does my belly or my bum look big'. You just ... saying. ,"And the shoot was great fun. They had ...
Cached Medicine News:
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Meridian Microruptor V Nd: YAG laser system is indicated for posterior capsulotomy, peripheral iridotomy, and pupillary membranectomy procedures....
... method for determining color vision abnormalities and ... can be applied to many psychological and ... of four trays containing a total of ... incremental hue variation on one side and ...
Medicine Products: